138 related articles for article (PubMed ID: 34751450)
1. Contrast-Enhanced Ultrasound-Based Nomogram: A Potential Predictor of Individually Postoperative Early Recurrence for Patients With Combined Hepatocellular-Cholangiocarcinoma.
Guo HL; Lu XZ; Hu HT; Ruan SM; Zheng X; Xie XY; Lu MD; Kuang M; Shen SL; Chen LD; Wang W
J Ultrasound Med; 2022 Aug; 41(8):1925-1938. PubMed ID: 34751450
[TBL] [Abstract][Full Text] [Related]
2. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound.
Chen LD; Ruan SM; Liang JY; Yang Z; Shen SL; Huang Y; Li W; Wang Z; Xie XY; Lu MD; Kuang M; Wang W
World J Gastroenterol; 2018 Sep; 24(33):3786-3798. PubMed ID: 30197484
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Microvascular Invasion in Combined Hepatocellular-Cholangiocarcinoma Based on Pre-operative Clinical Data and Contrast-Enhanced Ultrasound Characteristics.
Chen Y; Lu Q; Zhu Y; Huang B; Dong Y; Wang W
Ultrasound Med Biol; 2022 Jul; 48(7):1190-1201. PubMed ID: 35397928
[TBL] [Abstract][Full Text] [Related]
4. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma.
Wen R; Lin P; Wu Y; Yin H; Huang W; Guo D; Peng Y; Liu D; He Y; Yang H
Eur J Radiol; 2022 Sep; 154():110415. PubMed ID: 35738166
[TBL] [Abstract][Full Text] [Related]
6. Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study.
Zheng C; Gu XT; Huang XL; Wei YC; Chen L; Luo NB; Lin HS; Jin-Yuan L
Radiol Med; 2023 Dec; 128(12):1460-1471. PubMed ID: 37747668
[TBL] [Abstract][Full Text] [Related]
7. Contrast-Enhanced Ultrasound for Differentiation Between Poorly Differentiated Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Guo HL; Zheng X; Cheng MQ; Zeng D; Huang H; Xie XY; Lu MD; Kuang M; Wang W; Xian MF; Chen LD
J Ultrasound Med; 2022 May; 41(5):1213-1225. PubMed ID: 34423864
[TBL] [Abstract][Full Text] [Related]
8. Nomogram based on Sonazoid contrast-enhanced ultrasound to differentiate intrahepatic cholangiocarcinoma and poorly differentiated hepatocellular carcinoma: a prospective multicenter study.
Wang S; Yao J; Li K; Yang H; Lu S; He G; Wu W; Cheng W; Jiang T; Ding H; Jing X; Yan Y; Liu F; Yu J; Han Z; Cheng Z; Tan S; Li X; Dou J; Li Y; Qi E; Zhang Y; Liang P; Yu X
Abdom Radiol (NY); 2023 Oct; 48(10):3101-3113. PubMed ID: 37436451
[TBL] [Abstract][Full Text] [Related]
9. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
[TBL] [Abstract][Full Text] [Related]
10. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Yang J; Zhang YH; Li JW; Shi YY; Huang JY; Luo Y; Liu JB; Lu Q
World J Gastroenterol; 2020 Dec; 26(46):7325-7337. PubMed ID: 33362387
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive radiomics nomogram for predicting survival of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
Tang YY; Zhao YN; Zhang T; Chen ZY; Ma XL
World J Gastroenterol; 2021 Nov; 27(41):7173-7189. PubMed ID: 34887636
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia predicts an adverse prognosis in patients with combined hepatocellular carcinoma and cholangiocarcinoma after surgery.
Hou GM; Jiang C; Du JP; Yuan KF
Cancer Med; 2022 Jan; 11(2):317-331. PubMed ID: 34866356
[TBL] [Abstract][Full Text] [Related]
13. A multi-parameter intrahepatic cholangiocarcinoma scoring system based on modified contrast-enhanced ultrasound LI-RADS M criteria for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
Wang LF; Guan X; Shen YT; Zhou BY; Sun YK; Li XL; Yin HH; Lu D; Ye X; Hu XY; Yang DH; Xia HS; Wang X; Lu Q; Han H; Xu HX; Zhao CK;
Abdom Radiol (NY); 2024 Feb; 49(2):458-470. PubMed ID: 38225379
[TBL] [Abstract][Full Text] [Related]
14. CT-based clinico-radiological nomograms for prognosis prediction in patients with intrahepatic mass-forming cholangiocarcinoma: a multi-institutional study.
Jiao CY; Zhang H; Ji GW; Xu Q; Lu M; Zhang B; Yang Y; Wang XH; Li XC
Eur Radiol; 2022 Dec; 32(12):8326-8338. PubMed ID: 35708837
[TBL] [Abstract][Full Text] [Related]
15. Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.
Huang XW; Huang Y; Chen LD; Wang Z; Yang Z; Liu JY; Xie XY; Lu MD; Shen SL; Wang W
J Med Ultrason (2001); 2018 Apr; 45(2):231-241. PubMed ID: 29052791
[TBL] [Abstract][Full Text] [Related]
16. DCE-MRI based radiomics nomogram for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma.
Zhou Y; Zhou G; Zhang J; Xu C; Zhu F; Xu P
Eur Radiol; 2022 Jul; 32(7):5004-5015. PubMed ID: 35128572
[TBL] [Abstract][Full Text] [Related]
17. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
[No Abstract] [Full Text] [Related]
18. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study.
Zhou YW; Li QF; Chen YY; Wang K; Pu D; Chen XR; Li CH; Jiang L; Wang Y; Li Q; Yang Y; Gou HF; Bi F; Liu JY; Chen Y; Qiu M
Eur J Surg Oncol; 2022 Jul; 48(7):1559-1566. PubMed ID: 35115213
[TBL] [Abstract][Full Text] [Related]
20. Letter to the editor Re "Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study".
Xie Y; Wang J; Zou Y
Radiol Med; 2024 Apr; 129(4):665-666. PubMed ID: 38512607
[No Abstract] [Full Text] [Related]
[Next] [New Search]
